Staedtisches Krankenhaus Kiel GmbH — Clinical Trial Site

16 Registered trials

10 Currently recruiting

Organisation

Staedtisches Krankenhaus Kiel GmbH

Location

Kiel, Germany

Identifier

ORG-100025890

Address

Chemnitzstrasse 33, Schreventeich, 24116, Germany

Departments

#6007: II. Medizinische Klinik
2. Medizinische Klinik
2. Medizinische Klinik (Department of Internal Medicine)
2. Medizinische Klinik / Hämatologisch-onkologische Ambulanz
2024; 2. Medizinische Klinik
2504:2. Medizinische Klinik
Chirurgie
Department of Internal Medicine
Frauenklinik
Gynaecology
Internal Medicine
N/A
Oncology

Clinical trials at this site (16)

Search interface

A trial to learn if odronextamab is safe and well-tolerated and how well it works compared to rituximab combined with different types of che… Recruiting

2022-502660-20-00 Follicular lymphoma 5 2024-01-23
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
A Phase 3 Study of I-DXd in Subjects with Relapsed SCLC Recruiting

2023-509628-16-00 Small Cell Lung Cancer (SCLC) 5 2026-05-07
A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe… Recruiting

2023-503412-33-00 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small 5 2024-03-29
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
Asciminib Roll-over Study Recruiting

2023-507557-16-00 chronic myelogenous leukemia (CML) or Philadelphia Chro 5 2022-08-31
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituxim… Recruiting

2024-510690-16-00 Relapsed/refractory follicular lymphoma 5 2022-01-31
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 female and male adult patients with acute myeloid leuke 9 2020-09-02
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
A PHASE 1/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB… Ended

2023-506139-13-00 Treatment naïve patients with MF 5 2024-01-04
A Phase II clinical trial comparing the efficacy of RO7198457 versus watchful waiting in patients with ctDNA positive, resected Stage II (hi… Ended

2023-509516-28-00 Stage II/Stage III rectal cancer or Stage II (high risk 4 2021-02-22
Asciminib treatment optimization in ≥ 3rd line CML-CP Ended

2024-511381-36-00 Chronic Myelogenous Leukemia in chronic phase (CML-CP) 5 2021-10-13
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
First-line chemotherapy plus pembrolizumab and olaparib for BRCA nonmutated advanced EOC Ended

2022-502124-52-00 Advanced epithelial ovarian cancer 5 2018-12-18